Inhibrx Reports Third Quarter 2026 Financial Results

The San Diego biotech posted a $38.7 million net loss for the quarter while advancing two clinical-stage programs.

Updated on Nov. 14, 2026 in Biotech

Bold flat-color editorial illustration of a single stainless-steel bioreactor vessel on a pale floor, evoking a San Diego biotech company's quarterly financial results.
Inhibrx Biosciences reported a $38.7 million net loss and $2 million in revenue for the third quarter of 2026 while advancing two clinical-stage programs. AI Illustration. Upload story photo >

Inhibrx Biosciences, Inc. (Nasdaq: INBX) reported financial results for the third quarter of 2026, announced November 13, 2026. The company recorded total revenue of $2 million and a net loss of $38.7 million for the three months ended September 30, 2026.

Why it matters

The results show a company with substantial losses and a stockholders' deficit while it advances two programs in ongoing clinical trials. Its cash position and debt load will shape how long it can continue funding its pipeline.

The quarter's $2 million in revenue set against a $38.7 million net loss shows the company is still pre-commercial, and its $(85.9) million stockholders' deficit against $199.5 million in cash shows how heavily it relies on debt. The filing does not indicate when its pipeline candidates may reach later-stage data.

The players

Inhibrx Biosciences, Inc.

A San Diego-based clinical-stage biotechnology company traded on Nasdaq under the symbol INBX, focused on engineered protein therapeutics for cancer.

The details

Inhibrx develops therapeutic candidates using its proprietary protein engineering platforms, including ozekibart (INBRX-109) and ordastobart (INBRX-106), which use multivalent formats. The company reported total revenue of $2 million for the quarter and a net loss of $38.7 million.

Timeline

  1. September 30, 2026: Third quarter 2026 reporting period ends.

  2. November 13, 2026: Third quarter 2026 financial results announced.

The Tech Race

Inhibrx's multivalent protein formats, which allow precise valency optimization for each target, place its candidates among a wave of engineered biologics competing for solid-tumor indications. The quarter's losses show the capital intensity of advancing such platforms toward approval.

For patients with head and neck or lung cancers, the candidates named in this report are still in clinical development and are not available as treatments. The results do not change current treatment options or access.

The takeaway

Clinical-stage biotechs often post large losses for years before any product revenue appears, so quarterly losses alone do not signal the outcome of a program. Readers tracking the sector should watch cash runway and upcoming trial milestones, which the filing does not date.

Further reading

Explore more Biotech coverage for context on San Diego's drug development companies.